TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20859612

Group type: COMPARATOR
Intervention: Participants born at term and small for gestational age
Number of subjects: 4744

Group type: EXPERIMENTAL
Intervention: Increase in birthweight by 1 kg
Number of subjects: 4744

Group type: EXPERIMENTAL
Intervention: Ponderal index at birth
Number of subjects: 4744

Group type: EXPERIMENTAL
Intervention: Low birthweight
Number of subjects: 4744

Group type: EXPERIMENTAL
Intervention: Prematurity
Number of subjects: 4744

Group type: EXPERIMENTAL
Intervention: Birthweight z-scores
Number of subjects: 4744
Study: 20860020

Group type: EXPERIMENTAL
Intervention: Darifenacin treatment
Number of subjects: 473
Study: 20861505

Group type: EXPERIMENTAL
Intervention: High-sodium plus potassium dietary intervention
Number of subjects: 1906
Study: 20862748

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg orally, once daily, on Schedule 4/2
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 321
Study: 20863431

Group type: EXPERIMENTAL
Intervention: octagam 10% 1 g/kg/day on two consecutive days; maximum infusion rate of 0·12 ml/kg/minute
Number of subjects: 116
Study: 20869813

Group type: EXPERIMENTAL
Intervention: Coping drinking motives at 12 months
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Baseline victimisation
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Alcohol-related problems at 12 months
Number of subjects: 324
Study: 20871389

Group type: EXPERIMENTAL
Intervention: NRTI-containing regimens (including zidovudine, tenofovir, or stavudine)
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: NRTI-sparing regimens (haplogroup W)
Number of subjects: 757
Study: 20874659

Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase (ALP)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Percentage body fat
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: White blood cell count
Number of subjects: 233
Study: 20874827

Group type: EXPERIMENTAL
Intervention: Peptide LY6K-177, peptide TTK-567, and CpG-7909 (level-1; 0, level-2; 0.02, level-3; 0.1 mg/kg)
Number of subjects: 9
Study: 20875102

Group type: EXPERIMENTAL
Intervention: IDD-3 (8 doses of autologous monocyte-derived matured DC with GM-CSF and IL-13, pulsed with melanoma cell line lysates, matured with interferon gamma)
Number of subjects: 33
Study: 20876174

Group type: EXPERIMENTAL
Intervention: Clinical prediction model for invasive candidiasis
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Clinician judgment
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Invasive candidiasis
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Positive blood culture
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Positive urine culture
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Mortality rate comparison
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Incidence of candida
Number of subjects: 1515

Group type: EXPERIMENTAL
Intervention: Potentially modifiable risk factors
Number of subjects: 1515
Study: 20876373

Group type: EXPERIMENTAL
Intervention: E. coli (fecal flora)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: CNS (nasal flora)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: α-hemolytic streptococci (pharyngeal flora)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Overall resistance
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Risk factors for E. coli
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Risk factors for CNS
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Risk factors for pharyngeal streptococci
Number of subjects: 555
Study: 20876670

Group type: EXPERIMENTAL
Intervention: Supplemental water intake prescribed to achieve a mean urine osmolality of 285 ± 45 mosm/kg
Number of subjects: 8
Study: 20877297

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 1914

Group type: EXPERIMENTAL
Intervention: Citalopram/Escitalopram (SSRIs)
Number of subjects: 1914
Study: 20877651

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outer retinal thickness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurodegeneration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photoreceptor layer lesions
Number of subjects: 0
Study: 20878175

Group type: EXPERIMENTAL
Intervention: Focal increased FAF (Group 1, 31 cases)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Focal decreased FAF (Group 2, 32 cases)
Number of subjects: 63
Study: 20879830

Group type: EXPERIMENTAL
Intervention: Bergen Psychosis Project (BPP) patients
Number of subjects: 218

Group type: COMPARATOR
Intervention: Nord-Trøndelag Health Study 1995-97 (HUNT2) subjects
Number of subjects: 218
Study: 20879880

Group type: EXPERIMENTAL
Intervention: Reduced chemotherapy (4 cycles for favorable features, 8 cycles for unfavorable features)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Reduced chemotherapy
Number of subjects: 479
Study: 20879963

Group type: EXPERIMENTAL
Intervention: Insulin pump therapy
Number of subjects: 54
Study: 20880595

Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted partial intracapsular tonsillectomy and adenoidectomy (PITA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bovie electrocautery complete tonsillectomy and adenoidectomy (T&A)
Number of subjects: 30
Study: 20881025

Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis system on
Number of subjects: 27

Group type: COMPARATOR
Intervention: Residual native vision (system off)
Number of subjects: 27
Study: 20881067

Group type: EXPERIMENTAL
Intervention: Adipose tissue α-tocopherol concentrations measured in adipose tissue samples
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adipose tissue triglyceride concentrations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adipose tissue cholesterol concentrations
Number of subjects: 8
Study: 20881264

Group type: EXPERIMENTAL
Intervention: CDB-2914
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 20881648

Group type: EXPERIMENTAL
Intervention: Pulmonary metastasectomy
Number of subjects: 43
Study: 20881954

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A specific) with pazopanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omeprazole (CYP2C19 specific) with pazopanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (CYP1A2 specific) with pazopanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S-warfarin (CYP2C9 specific) with pazopanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (CYP2D6 specific) with pazopanib
Number of subjects: 0
Study: 20883227

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 80 mg + Lisinopril 40 mg
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 80 mg + Lisinopril 20 mg
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 80 mg + Lisinopril 10 mg
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 40 mg + Lisinopril 40 mg
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 20 mg + Lisinopril 40 mg
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 20 mg + Lisinopril 20 mg
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 40 mg + Lisinopril 20 mg
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 40 mg + Lisinopril 10 mg
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 20 mg + Lisinopril 10 mg
Number of subjects: 656

Group type: COMPARATOR
Intervention: Carvedilol CR 80 mg
Number of subjects: 656

Group type: COMPARATOR
Intervention: Lisinopril 40 mg
Number of subjects: 656
Study: 20883586

Group type: EXPERIMENTAL
Intervention: Offspring of bipolar parents (O-BD)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Offspring of major depressive disorder (O-UNI)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Entire group (including O-BD and O-UNI)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Offspring with no significant psychiatric or medical problems (O-WELL)
Number of subjects: 94
Study: 20883929

Group type: EXPERIMENTAL
Intervention: High-dose dobutamine stress MRI
Number of subjects: 1493
Study: 20884191

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 1759

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 1759
Study: 20884379

Group type: EXPERIMENTAL
Intervention: QRS score = 0 (no scar)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: QRS score (scar absence) combined with ejection fraction (≥ 25%)
Number of subjects: 797
Study: 20885393

Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Nonoverweight children
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Higher BMI percentile scores and percent body fat at baseline
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: African-American girls
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: White boys and girls, African-American boys
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Estimates of obesity and overweight prevalence
Number of subjects: 451
Study: 20885982

Group type: EXPERIMENTAL
Intervention: Repetitive behaviours (RB) classified as tic-like, OCD-like, or mixed based on evaluations using YBOCS symptom checklist and M.I.N.I.
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: OCD-like behaviours correlated with higher scores of complex tics, neuroleptic and SSRIs treatment frequency, and less successful socio-professional adaptation.
Number of subjects: 166
Study: 20886200

Group type: EXPERIMENTAL
Intervention: Long-acting bronchodilator (LABD) monotherapy
Number of subjects: 1084
Study: 20888065

Group type: EXPERIMENTAL
Intervention: PF-3512676 (0.08, 0.16, 0.24, 0.28, 0.32, or 0.36 mg/kg) administered as 24 weekly subcutaneous injections
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PF-3512676
Number of subjects: 28
Study: 20888102

Group type: EXPERIMENTAL
Intervention: Once-daily extended-release niacin
Number of subjects: 0
Study: 20888135

Group type: EXPERIMENTAL
Intervention: Extended model including CEA and IL-6
Number of subjects: 106

Group type: COMPARATOR
Intervention: Baseline model
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Validation cohort for extended model
Number of subjects: 106

Group type: COMPARATOR
Intervention: Validation cohort for baseline model
Number of subjects: 106
Study: 20889909

Group type: EXPERIMENTAL
Intervention: COPD subjects
Number of subjects: 2118

Group type: COMPARATOR
Intervention: Smokers without COPD
Number of subjects: 2118

Group type: COMPARATOR
Intervention: Nonsmokers without COPD
Number of subjects: 2118
Study: 20890049

Group type: EXPERIMENTAL
Intervention: 1-stent technique
Number of subjects: 1668

Group type: COMPARATOR
Intervention: 2-stent technique
Number of subjects: 1668
Study: 20890189

Group type: EXPERIMENTAL
Intervention: Daptomycin at 8 mg/kg intravenously over 30 mins
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Daptomycin at 8 mg/kg every 48 hrs
Number of subjects: 8
Study: 20919852

Group type: EXPERIMENTAL
Intervention: Busulfan AUC of 5800 µmol-min/L
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Busulfan AUC of 6800 µmol-min/L
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Busulfan test dose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Busulfan conditioning dose 1 pharmacokinetics
Number of subjects: 36

Group type: COMPARATOR
Intervention: Busulfan standard regimens
Number of subjects: 36
Study: 20920156

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (0.5 mg/24 h to 4 mg/24 h, mean daily dose 2.93 ± 1.14 mg/24 h after 2 years)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 295
Study: 20920370

Group type: EXPERIMENTAL
Intervention: IV alpha-1 antitrypsin (AAT) augmentation therapy (Alfalastin® or Prolastin®)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 20920778

Group type: EXPERIMENTAL
Intervention: IL-4/IL-13 antagonist
Number of subjects: 0
Study: 20921437

Group type: EXPERIMENTAL
Intervention: Pacemaker generator replacements (cohort 1)
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator generator replacements (cohort 2)
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Upgrades to or revised cardiac resynchronization therapy device (cohort 2)
Number of subjects: 1744

Group type: COMPARATOR
Intervention: Cohort 1 (infection rates)
Number of subjects: 1744

Group type: COMPARATOR
Intervention: Cohort 2 (infection rates)
Number of subjects: 1744
Study: 20921541

Group type: EXPERIMENTAL
Intervention: Blood-based gene expression test for obstructive CAD
Number of subjects: 526
Study: 20921879

Group type: EXPERIMENTAL
Intervention: Detected illness
Number of subjects: 265
Study: 20921906

Group type: EXPERIMENTAL
Intervention: Deferiprone (50 to 100 mg/kg/d)
Number of subjects: 100
Study: 20922800

Group type: EXPERIMENTAL
Intervention: Apricoxib 400 mg/day plus erlotinib 150 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Apricoxib 100 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Apricoxib 200 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Apricoxib 400 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prior EGFR-directed therapies
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Urinary PGE-M
Number of subjects: 20
Study: 20923256

Group type: EXPERIMENTAL
Intervention: PTH(1-84) 100 µg once daily for 36 months
Number of subjects: 0
Study: 20923544

Group type: EXPERIMENTAL
Intervention: Apatinib (YN968D1) 850 mg once daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Apatinib (YN968D1) 750 mg once daily
Number of subjects: 46
Study: 20923561

Group type: COMPARATOR
Intervention: Healthy control subjects (Group 1)
Number of subjects: 51

Group type: COMPARATOR
Intervention: CKD patients with e-GFR ≤ 90 ml/min (Group 2)
Number of subjects: 51

Group type: COMPARATOR
Intervention: CKD patients with 60 ml/min ≤ e-GFR < 90 ml/min (Group 3)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CKD patients with 15 ml/min ≤ e-GFR < 60 ml/min (Group 4)
Number of subjects: 51
Study: 20923629

Group type: EXPERIMENTAL
Intervention: Minocycline augmentation of pharmacotherapy
Number of subjects: 0
Study: 20924570

Group type: EXPERIMENTAL
Intervention: Vaginal suppository containing 1,200 mg miconazole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 20925545

Group type: EXPERIMENTAL
Intervention: Functional dystrophin transgene delivery
Number of subjects: 6
Study: 20925950

Group type: EXPERIMENTAL
Intervention: Dihydrocapsiate (DCT) 9 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dihydrocapsiate (DCT) 3 mg/day
Number of subjects: 33
Study: 20926522

Group type: EXPERIMENTAL
Intervention: Iron-fortified sorghum-based meal
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Asymptomatic P. falciparum parasitemia
Number of subjects: 23
Study: 20926537

Group type: EXPERIMENTAL
Intervention: Hormonal interventions (specific hormones not detailed)
Number of subjects: 0
Study: 20926818

Group type: EXPERIMENTAL
Intervention: Microperimetry treatment (one eye randomized to treatment)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Microperimetry assessments every 6 months over 24 months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Microperimetry assessments
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Growth of GA lesion area
Number of subjects: 10
Study: 20927368

Group type: EXPERIMENTAL
Intervention: MRI of the right coronary artery (RCA) and vessel wall (MR-CVW)
Number of subjects: 48
Study: 20930086

Group type: EXPERIMENTAL
Intervention: Autologous MSC infusion
Number of subjects: 2
Study: 20930628

Group type: EXPERIMENTAL
Intervention: IDO inhibitors (oral administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High IDO expression in tumor cells
Number of subjects: 0
Study: 20932222

Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg to 120 mg daily
Number of subjects: 667
Study: 20932224

Group type: EXPERIMENTAL
Intervention: Oral salmon calcitonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal formulation of salmon calcitonin
Number of subjects: 0
Study: 20932316

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 500

Group type: COMPARATOR
Intervention: Medically treated controls
Number of subjects: 500

Group type: COMPARATOR
Intervention: Wait-listed controls
Number of subjects: 500
Study: 20934233

Group type: EXPERIMENTAL
Intervention: Irinotecan (150 mg/m(2))/oxaliplatin (85 mg/m(2)) followed by etoposide (100 mg/m(2)×3)/carboplatin (AUC 6)
Number of subjects: 26
Study: 20935227

Group type: EXPERIMENTAL
Intervention: Resveratrol 0.5 g daily for 29 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resveratrol 1.0 g daily for 29 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resveratrol 2.5 g daily for 29 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resveratrol 5.0 g daily for 29 days
Number of subjects: 40
Study: 20937120

Group type: EXPERIMENTAL
Intervention: IMRT and carbon ion boost (24 GyE carbon ions in 8 fractions and IMRT 50 Gy at 2.0 Gy/fraction)
Number of subjects: 54
Study: 20937930

Group type: EXPERIMENTAL
Intervention: Somatic symptom burden measured using a 22-item scale.
Number of subjects: 405
Study: 20937945

Group type: EXPERIMENTAL
Intervention: Intrathecal and intravenous administration of autologous mesenchymal stem cells (MSCs). Mean (SD) of 63.2 × 10(6) (2.5 × 10(6)) MSCs injected. Follow-up ≤25 months.
Number of subjects: 34
Study: 20938098

Group type: EXPERIMENTAL
Intervention: 3-month dual antiplatelet therapy (aspirin 100-200mg + clopidogrel 75 mg daily)
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Clopidogrel discontinued at 3 months
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Clopidogrel continued for longer than 3 months
Number of subjects: 823
Study: 20939723

Group type: EXPERIMENTAL
Intervention: Express LD Vascular stent
Number of subjects: 151
Study: 20939732

Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 8
Study: 20940416

Group type: EXPERIMENTAL
Intervention: Tumor cells from lymph nodes (LN)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tumor proliferation quantified by E2F and c-MYC target genes and Ki67 staining
Number of subjects: 24
Study: 20943702

Group type: EXPERIMENTAL
Intervention: Preconception SHBG levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Waist circumference, BMI, blood pressure, plasma glucose, insulin, HOMA-IR
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasma SHBG
Number of subjects: 50
Study: 20943799

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D [25(OH)D] concentrations measured during winter
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D [25(OH)D] concentrations measured during summer
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Seasonal variation in 25(OH)D concentrations
Number of subjects: 510
Study: 20946651

Group type: EXPERIMENTAL
Intervention: Personal Concerns Inventory interview plus treatment as usual
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 100
Study: 20947286

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily with 12 weeks of behavioral counseling
Number of subjects: 32
Study: 20948452

Group type: EXPERIMENTAL
Intervention: F-HX4 (422±142 MBq in humans; 189±3 MBq in monkeys)
Number of subjects: 7
Study: 20950306

Group type: EXPERIMENTAL
Intervention: Bicalutamide (150 mg) monotherapy
Number of subjects: 42
Study: 20950392

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 20952478

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0
Study: 20952514

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bortezomib 1 mg/m2
Number of subjects: 16
Study: 20952517

Group type: EXPERIMENTAL
Intervention: Liposomal cytarabine (50 mg) given intrathecally together with systemic or intrathecal dexamethasone once every 2 weeks
Number of subjects: 19
Study: 20952518

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 50
Study: 20952687

Group type: EXPERIMENTAL
Intervention: UCB Treg infusion (0.1-30 × 10(5) UCB Treg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Historical controls without Treg
Number of subjects: 23
Study: 20955442

Group type: EXPERIMENTAL
Intervention: Adalimumab (160/80 mg at weeks 0/2 for induction, 40 mg every other week for maintenance)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 673
Study: 20955461

Group type: EXPERIMENTAL
Intervention: Hib vaccination (universal vaccination introduced in 1992)
Number of subjects: 5703
Study: 20955619

Group type: EXPERIMENTAL
Intervention: E. coli RNA fragments (20, 40, or 60 mg starting dose, escalated to a maximum of 80 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Yeast RNA fragments (20, 40, or 60 mg starting dose, escalated to a maximum of 80 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E. coli RNA fragments (60 and 80 mg doses)
Number of subjects: 30
Study: 20955704

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 85
Study: 20956472

Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg orally twice a day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: non-neoadjuvant treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 14
Study: 20956633

Group type: EXPERIMENTAL
Intervention: MelaFind
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: MelaFind (including borderline lesions)
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Dermatologists
Number of subjects: 1383
Study: 20956641

Group type: EXPERIMENTAL
Intervention: Vitamin D status in patients with BCNS
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vitamin D levels in patients with BCNS
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Risk of vitamin D deficiency in patients with BCNS
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vitamin D levels in overweight patients with BCNS
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vitamin D levels in patients with BCNS by season
Number of subjects: 41